Impact of bronchodilator therapy on diaphragmatic function in sleep in COPD
We examined the effect of nocturnal BD on inspiratory neural drive (IND) in supine wakefulness (W) and sleep (non-rapid eye movement stage 2, N2) at equivalent time-points overnight.20 patients with COPD (FRC 147±32%pred; post-BD FEV1 56±16%pred) completed a double-blinded, placebo-controlled crossover study with two 2wk treatment arms (BD: aclidinium bromide/formoterol fumarate 400/12mcg, or Placebo, PL), polysomnography, and measurement of IND (EMGdi,%max) and Pdi(%max) during stable breathing in W at 2, 6 & 10h post-dose and in N2 directly before W testing at 6 & 10h post-dose.BD (vs PL) improved I...
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Domnik, N. J., Scheeren, R., Taylor, S., Driver, H., Crinion, S., Neder, J. A., O'Donnell, D. Tags: Clinical respiratory physiology, exercise and functional imaging Source Type: research
Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries
Conclusion: AB, AB/FF users showed similar characteristics to those of other LAMA users. Compared with LABA and LABA/ICS users, AB and AB/FF users were older, had a higher frequency of severe COPD, chronic comorbidities, and use of COPD comedications. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Rebordosa, C., Rubino, A., Witzleb, A. J., Olesen, M., Plana, E., Aguado, J., Saigi, N., Daoud, S. Z., Lei, A., Perez-Gutthann, S., Schink, T., Kristiansen, N. S., Pottegard, A., Rivero-Ferrer, E. Tags: Epidemiology Source Type: research
Deterioration of Nighttime Respiratory Mechanics in Chronic Obstructive Pulmonary Disease: Impact of Bronchodilator Therapy.
Abstract
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is associated with nighttime respiratory symptoms, poor sleep quality, and increased risk of nocturnal mortality. Overnight deterioration of inspiratory capacity (IC) and forced expiratory volume in 1 second (FEV1) have previously been documented. However, the precise nature of this deterioration and mechanisms by which evening bronchodilators may mitigate this have not been studied.
RESEARCH QUESTION: To determine the effect of evening dosing of dual, long-acting bronchodilators on detailed nocturnal respiratory mechanics and inspir...
Source: Chest - June 26, 2020 Category: Respiratory Medicine Authors: Domnik NJ, James MD, Scheeren RE, Ayoo GA, Taylor SM, Di Luch AT, Milne KM, Vincent SG, Phillips DB, Elbehairy AF, Crinion SJ, Driver HS, Neder JA, O'Donnell DE Tags: Chest Source Type: research
2019 Year in Review: Aerosol Therapy.
Abstract
Relevant publications related to medicinal and toxic aerosols are discussed in this review. Treatment of COPD includes a combination of long-acting bronchodilators and long-acting muscarinic antagonists. A combination of aclidinium bromide and formoterol fumarate was approved in the United States. The combination was superior to its components alone, as well as tiotropium and a salmeterol-fluticasone combination. Increased risk of an asthma exacerbation was reported in children exposed to electronic nicotine delivery systems. A smart inhaler capable of recording inspiratory flow was approved in th...
Source: Respiratory Care - April 30, 2020 Category: Respiratory Medicine Authors: Berlinski A Tags: Respir Care Source Type: research
Aclidinium Bromide and Formoterol Fumarate for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease.
PMID: 31951778 [PubMed - as supplied by publisher] (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - January 16, 2020 Category: Drugs & Pharmacology Authors: Haley R, Gupta N, Sethi S Tags: Expert Rev Clin Pharmacol Source Type: research
Overnight deterioration of supine respiratory mechanics in COPD: impact of nocturnal aclidinium bromide/formoterol fumarate
Conclusions: Overnight respiratory mechanics deteriorated progressively in COPD vs health. Nocturnal AB/FF provided sustained bronchodilatation and deflation, permitting equivalent ventilation with less inspiratory neural drive. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Domnik, N., James, M., Ciavaglia, C., Driver, H., Crinion, S., Neder, J. A., ODonnell, D. Tags: Clinical respiratory physiology, exercise and functional imaging Source Type: research
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
Date: September 23, 2019
Issue #:
1581Summary:
The FDA has approvedDuaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication. (Source: The Medical Letter)
Source: The Medical Letter - August 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Anoro Ellipta Bevespi Aerosphere COPD Duaklir Pressair Formoterol Glycopyrrolate indacaterol Inspiolto Respimat Long-acting beta2-agonists Stiolto Respimat tiotropium/olodaterol Ultibro Breezehaler umeclidinium Utibr Source Type: research
Pharmaceutical Approval Update.
Authors: Choy M
Abstract
Mavenclad (cladribine) tablets for relapsing MS forms; Duaklir Pressair (aclidinium bromide/formoterol fumarate) inhalant for COPD; Evenity (romosozumab-aqqg) injection for osteoporosis.
PMID: 31258309 [PubMed] (Source: P and T)
Source: P and T - July 2, 2019 Category: Drugs & Pharmacology Tags: P T Source Type: research
Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway.
CONCLUSION: Our results reveals that Aclidinium Bromide behaves as a novel M3R antagonist, and may inhibit lung cancer cell growth by regulating the PI3K/AKT signaling pathway, which sheds some light on that it might be a potential therapeutic agent for lung cancer.
PMID: 31128006 [PubMed - in process] (Source: Journal of B.U.ON.)
Source: Journal of B.U.ON. - May 29, 2019 Category: Cancer & Oncology Tags: J BUON Source Type: research
Effect of Aclidinium Bromide on Cardiovascular Events and COPD Exacerbations in High-Risk Patients
This randomized clinical trial compares the effects of the long-acting muscarinic antagonist aclidinium bromide vs placebo on major adverse cardiovascular events and chronic obstructive pulmonary disease (COPD) exacerbations in patients with COPD and increased cardiovascular risk. (Source: JAMA)
Source: JAMA - May 7, 2019 Category: General Medicine Source Type: research
Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom
Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA). Although the initial potential increased cardiovascular and mortality risk among users of tiotropium has been ruled out by several observational studies, and clinical trials, there are still concerns related to the use of newer LAMA medications. The current study aimed to evaluate the risk of death among users of aclidinium and other LAMAs. (Source: Respiratory Medicine)
Source: Respiratory Medicine - April 25, 2019 Category: Respiratory Medicine Authors: Cristina Rebordosa, Jaume Aguado, Estel Plana, Steven Thomas, Ana Frances, Alejhandra Lei, Esther Garc ía-Gil, Javier Nuevo, Susana Perez-Gutthann, Jordi Castellsague Source Type: research
Single Inhaler LABA/LAMA for COPD
Conclusions of that meta-analysis should be interpreted with great caution because of differences in population studied, and differences in primary and co-primary outcomes.
A recent comparison meta-analysis was not conclusive due to the heterogeneity of phase III studies and the few number of studies for some of the investigated drugs (ACL/FF and GLY/FF in particular), but confirmed that dual bronchodilation was always more effective than LABA or LAMA alone, both in lung function and quality of life indices (Calzetta et al., 2016). This meta-analysis suggested that among the different FDCs may exist a gradient of effectiv...
Source: Frontiers in Pharmacology - April 24, 2019 Category: Drugs & Pharmacology Source Type: research
Aclidinium bromide inhibits proliferation of osteosarcoma cells through regulation of PI3K/Akt pathway.
CONCLUSIONS: Therefore, the current study reveals that aclidinium bromide might inhibit osteosarcoma cell growth by regulating the PI3K/AKT signaling pathway, which suggests aclidinium bromide is a potential chemotherapeutic agent for osteosarcoma.
PMID: 30657552 [PubMed - in process] (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - January 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
CONCLUSIONS: FDC improved dyspnoea and lung function compared to aclidinium, formoterol or placebo, and this translated into an increase in the number of responders on combination treatment. Quality of life was better with combination compared to formoterol or placebo. There was no evidence of a difference between FDC and monotherapy or placebo for exacerbations, hospital admissions, mortality, non-fatal SAEs or adverse events. Studies reported a lower risk of moderate exacerbations and adverse events with FDC compared to formoterol; however, larger studies would yield a more precise estimate for these outcomes.
PM...
Source: Cochrane Database of Systematic Reviews - December 11, 2018 Category: General Medicine Authors: Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN Tags: Cochrane Database Syst Rev Source Type: research
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Conclusions: In pts with COPD, AB was non-inferior to TIO in improving trough FEV1 and had similar efficacy for other bronchodilation and QoL outcomes at Wk 24. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Sethi, S., Kerwin, E., Watz, H., Ferguson, G. T., Mroz, R., Segarra, R., Molins, E., Jarreta, D., Garcia-Gil, E. Tags: Airway pharmacology and treatment Source Type: research
